Key facts
- Yili Pharmaceutical’s last known valuation is $35.3M (Dec 2024).
- It has raised $42.3M; the latest was Early Stage VC ($14.5M) in Mar 2026.
- Notable investors include SND Ventures Group, YuanBio Venture Capital, Tailong VC, Shanghai Guofang Private Equity Fund Management Company, BOHE Angel Fund — 16 tracked in total.
- Status: Privately Held (backing).
- ·The complete investor list — 16 names
- ·Watchlist + deal alerts for Yili Pharmaceutical
- ·The full record, as it builds
Funding rounds
No funding rounds for Yili Pharmaceutical are on record yet — either the company hasn't raised institutional capital, or the raise hasn't surfaced in our sources.
About Yili Pharmaceutical
Developer of radiopharmaceuticals intended for diagnostic and therapeutic agents for infectious and chronic diseases. The company specializes in targeted radiotracers, therapeutic radioisotope formulations, molecular imaging agents, and precision treatment compounds, thereby supporting accurate diagnosis and effective treatment, contributing to improved patient outcomes and longer, healthier lives.
- Sector
- Healthcare
- HQ
- Shanghai, China
- Founded
- 2024
- Ownership
- Privately Held (backing)
Yili Pharmaceutical doesn't have a composite mark yet — a PA Mark is published once enough pricing inputs exist (trade prints, fund marks, round prices). The rest of the record below builds toward it.
Recorded secondary trades
No secondary trades in Yili Pharmaceutical shares have been recorded yet. When a print lands — third-party, direct report, or platform — it appears here with structure, source, and price.
Institutional fund marks
No SEC-registered fund has reported a fair-value mark on Yili Pharmaceutical in its N-PORT filings yet. We sweep new filings monthly.